Metaxalone (Metaxalone) Patent Expiration, LOE Window & CMS Spending
Metaxalone (Metaxalone) by Primus: FDA Orange Book LOE 2043-05-14, 6 AB generics, $10.2M 2024 CMS Part D & Medicaid spend, and $3,750 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Primus |
| FDA Application & Pathway | N022503 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2043-05-14 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 6 |
| 2024 CMS Total Public Spend | $10.2M |
| 2024 Medicare Part D Spend | $8.5M |
| 2024 Medicaid Spend | $1.7M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($3,750 intro WAC) |